3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
2429
Neoplasms
1840
Carcinoma, Non-Small-Cell Lung
1615
Prostatic Neoplasms
1309
Colorectal Neoplasms
1147
Lung Neoplasms
991
Neoplasm Metastasis
836
Multiple Myeloma
801
Leukemia, Myeloid, Acute
777
Ovarian Neoplasms
682
Pancreatic Neoplasms
667
Melanoma
667
Squamous Cell Carcinoma of Head and Neck
592
Recurrence
568
Carcinoma, Hepatocellular
568
Brain Neoplasms
529
Glioblastoma
519
Stomach Neoplasms
504
Head and Neck Neoplasms
503
Triple Negative Breast Neoplasms
472
Lymphoma
462
Uterine Cervical Neoplasms
454
Carcinoma, Renal Cell
429
Precursor Cell Lymphoblastic Leukemia-Lymphoma
419
Lymphoma, Non-Hodgkin
392
Endometrial Neoplasms
385
Sarcoma
370
Lymphoma, Follicular
358
Urinary Bladder Neoplasms
356
Lymphoma, Large B-Cell, Diffuse
355
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
1 year
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled